X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (155) 155
Publication (26) 26
Newspaper Article (25) 25
Book / eBook (13) 13
Book Review (7) 7
Dissertation (7) 7
Book Chapter (2) 2
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (80) 80
humans (66) 66
female (51) 51
male (45) 45
oncology (38) 38
middle aged (37) 37
adult (31) 31
aged (30) 30
aged, 80 and over (18) 18
cancer (17) 17
abridged index medicus (16) 16
article (15) 15
medical and health sciences (14) 14
medicin och hälsovetenskap (14) 14
treatment outcome (14) 14
fda (13) 13
mutation (13) 13
risk factors (13) 13
regulatory issues (12) 12
united states (12) 12
chemotherapy (11) 11
drug approval (11) 11
health aspects (11) 11
child (10) 10
genetic aspects (10) 10
research (10) 10
survival (10) 10
analysis (9) 9
breast cancer (9) 9
child, preschool (9) 9
clinical medicine (9) 9
clinical trials (9) 9
drug therapy (9) 9
genetics (9) 9
klinisk medicin (9) 9
medical research (9) 9
medicine (9) 9
patients (9) 9
adolescent (8) 8
animals (8) 8
follow-up studies (8) 8
genome-wide association (8) 8
infant (8) 8
mortality (8) 8
risk (8) 8
surgery (8) 8
united states food and drug administration (8) 8
young adult (8) 8
adults (7) 7
children (7) 7
cohort studies (7) 7
confidence intervals (7) 7
double-blind method (7) 7
fda approval (7) 7
genetics & heredity (7) 7
management (7) 7
nutrition (7) 7
polymorphism, single nucleotide (7) 7
regulatory issues: fda (7) 7
studies (7) 7
trial (7) 7
women (7) 7
age (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
bmi (6) 6
body mass index (6) 6
development and progression (6) 6
diabetes (6) 6
fluorouracil (6) 6
genetic predisposition to disease (6) 6
genomes (6) 6
glucose (6) 6
heritability (6) 6
medicine and health sciences (6) 6
metformin (6) 6
ovarian cancer (6) 6
prospective studies (6) 6
twins (6) 6
aging (5) 5
antibodies, monoclonal - administration & dosage (5) 5
breast neoplasms - genetics (5) 5
disease (5) 5
disease progression (5) 5
disease-free survival (5) 5
endocrinology & metabolism (5) 5
epidemiology (5) 5
europe (5) 5
genotype (5) 5
hospitals (5) 5
immunology (5) 5
immunotherapy (5) 5
infants (5) 5
metastasis (5) 5
microbiology (5) 5
multidisciplinary sciences (5) 5
pain (5) 5
pembrolizumab (5) 5
physiological aspects (5) 5
proteins (5) 5
regulatory agencies (5) 5
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (6) 6
Gerstein Science - Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
OISE - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 11/2018, Volume 23, Issue 11, pp. 1366 - 1371
In 2017, the Food and Drug Administration granted accelerated approval of blinatumomab for the treatment of relapsed or refractory precursor B‐cell acute... 
Acute lymphoblastic leukemia | Drug approval | Blinatumomab | Philadelphia chromosome | ADULT PATIENTS | MULTICENTER | ONCOLOGY | SINGLE-ARM | FDA | Regulatory Issues
Journal Article
Blood, ISSN 0006-4971, 09/2017, Volume 130, Issue 11, pp. 1285 - 1289
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 05/2019
On November 21, 2018, the FDA approved glasdegib (Daurismo; Pfizer), a small-molecule Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC) for... 
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2019, Volume 25, Issue 10, pp. 2949 - 2955
On December 20, 2017, the FDA granted regular approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients... 
TRASTUZUMAB | ONCOLOGY | PACLITAXEL
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 05/2019, pp. JCO1900318 - JCO1900318
To assess the relationship among tumor response rate, overall survival, and the development of related adverse events of special interest (AESIs) or related... 
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 06/2019, Volume 25, Issue 11, pp. 3205 - 3209
The FDA approved ivosidenib (Tibsovo; Agios), a small-molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with... 
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2019, Volume 25, Issue 9, pp. 2685 - 2690
On August 3, 2017, the FDA granted regular approval to Vyxeos (also known as CPX-351; Jazz Pharmaceuticals), a liposomal formulation of daunorubicin and... 
REVISION | CLASSIFICATION | NEOPLASMS | ONCOLOGY | WORLD-HEALTH-ORGANIZATION
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 12, pp. 1225 - 1231
PurposeThe outcome and proportion of patients with bone-only (BO) metastatic breast cancer (MBC) has not been well described. We sought to describe the... 
RISK | COMPLICATIONS | MANAGEMENT | ONCOLOGY | DISEASE | ORIGINAL REPORTS
Journal Article
The Oncologist, ISSN 1083-7159, 04/2019, Volume 24, Issue 4, pp. 563 - 569
摘要 美国食品和药品管理局 (FDA) 分别于 2017 年 4 月和 5 月同意加速批准将阿特朱单抗和帕博利珠单抗用于治疗无法接受含顺铂化疗的局部晚期或转移性尿路上皮癌患者。上述批准以在两个单臂试验中显示的有效性和安全性数据为依据:IMvigor210(阿特朱单抗)和... 
Programmed death receptor‐1 antibody immunotherapy | Programmed death‐ligand 1 antibody | Pembrolizumab | Platinum‐containing chemotherapy | Locally advanced or metastatic urothelial carcinoma | Bladder cancer | Atezolizumab | Programmed death-ligand 1 antibody | Platinum-containing chemotherapy | Programmed death receptor-1 antibody immunotherapy | CARBOPLATIN | ONCOLOGY | UNFIT | CANCER | FDA | Regulatory Issues
Journal Article
The Oncologist, ISSN 1083-7159, 04/2018, Volume 23, Issue 4, pp. 496 - 500
Regorafenib is the first drug approved by the FDA for the treatment of hepatocellular carcinoma that has progressed on sorafenib and is expected to become a... 
Regorafenib | Hepatocellular carcinoma | Sorafenib | PLACEBO | ONCOLOGY | PHASE-3 TRIAL | DOUBLE-BLIND | 12 | 23 | FDA | Regulatory Issues
Journal Article
Blood, ISSN 0006-4971, 09/2017, Volume 130, Issue 11, pp. 1285 - 1289
Journal Article
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 2017, Volume 37, p. 216
Despite considerable interest and success in oncology drug development, the minority of patients with cancer diagnoses enroll in clinical trials. Multiple... 
United States | Humans | Patient Participation | Medical Oncology - standards | Clinical Trials as Topic | United States Food and Drug Administration - trends | Neoplasms - epidemiology | Neoplasms - drug therapy | Patient Selection
Journal Article
by Bojesen, Stig E and Pooley, Karen A and Johnatty, Sharon E and Beesley, Jonathan and Michailidou, Kyriaki and Tyrer, Jonathan P and Edwards, Stacey L and Pickett, Hilda A and Shen, Howard C and Smart, Chanel E and Hillman, Kristine M and Mai, Phuong L and Lawrenson, Kate and Stutz, Michael D and Lu, Yi and Karevan, Rod and Woods, Nicholas and Johnston, Rebecca L and French, Juliet D and Chen, Xiaoqing and Weischer, Maren and Nielsen, Sune F and Maranian, Melanie J and Ghoussaini, Maya and Ahmed, Shahana and Baynes, Caroline and Bolla, Manjeet K and Wang, Qin and Dennis, Joe and McGuffog, Lesley and Barrowdale, Daniel and Lee, Anew and Healey, Sue and Lush, Michael and Tessier, Daniel C and Vincent, Daniel and Bacot, Françis and Vergote, Ignace and Lambrechts, Sanina and Despierre, Evelyn and Risch, Harvey A and González-Neira, Anna and Rossing, Mary Anne and Pita, Guillermo and Doherty, Jennifer A and Alvarez, Nuria and Larson, Melissa C and Fridley, Brooke L and Schoof, Nils and Chang-Claude, Jenny and Cicek, Mine S and Peto, Julian and Kalli, Kimberly R and Broeks, Annegien and Armasu, Sebastian M and Schmidt, Marjanka K and Braaf, Linde M and Winterhoff, Boris and Nevanlinna, Heli and Konecny, Gottfried E and Lambrechts, Diether and Rogmann, Lisa and Guénel, Pascal and Teoman, Attila and Milne, Roger L and Garcia, Joaquin J and Cox, Angela and Shridhar, Vijayalakshmi and Burwinkel, Barbara and Marme, Frederik and Hein, Rebecca and Sawyer, Elinor J and Haiman, Christopher A and Wang-Gohrke, Shan and Anulis, Irene L and Moysich, Kirsten B and Hopper, John L and Odunsi, Kunle and Lindblom, Annika and Giles, Graham G and Brenner, Hermann and Simard, Jacques and Lurie, Galina and Fasching, Peter A and Carney, Michael E and Radice, Paolo and Wilkens, Lynne R and Swerdlow, Anthony and Goodman, Marc T and Brauch, Hiltrud and Garcia-Closas, Montserrat and Hillemanns, Peter and Winqvist, Robert and Dürst, Matthias and Devilee, Peter and Runnebaum, Ingo and Jakubowska, Anna and Lubinski, Jan and Mannermaa, Arto and Butzow, Ralf and ... and Gene Environm Interactimi Breast and Kathleen Cuningham Fdn Consortium and Australian Ovarian Canc Study and Epidemiological Study BRCA1 and Hereditary Breast Ovarian Canc Res and Genetic Modifiers Canc Risk BRCA1 and Australian Canc Study and Swedish Breast Canc Study SWE-BRCA and Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) and Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) and Gene Environment Interaction and Breast Cancer (GENICA) and Swedish Breast Cancer Study (SWE-BRCA) and Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE) and Australian Ovarian Cancer Study and Australian Cancer Study and Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) and The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) and Medicinska fakulteten and Umeå universitet and Institutionen för strålningsvetenskaper
Nature genetics, ISSN 1061-4036, 2013, Volume 45, Issue 4, pp. 371 - 384
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4534 - 4539
Journal Article
The oncologist, 12/2018, Volume 23, Issue 12, p. 1520
On November 6, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of adult patients with... 
Journal Article
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017, Volume 37, Issue 37, pp. 216 - 221
Despite considerable interest and success in oncology drug development, the minority of patients with cancer diagnoses enroll in clinical trials. Multiple... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.